Frank H. Laukien Purchases 1,920 Shares of Bruker Corporation (BRKR) Stock
Bruker Corporation (NASDAQ:BRKR) CEO Frank H. Laukien bought 1,920 shares of Bruker Corporation stock in a transaction dated Tuesday, May 16th. The shares were acquired at an average price of $25.88 per share, with a total value of $49,689.60. Following the completion of the purchase, the chief executive officer now owns 37,712,851 shares in the company, valued at approximately $976,008,583.88. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Bruker Corporation (NASDAQ BRKR) traded down 0.14% during midday trading on Friday, reaching $27.71. The company’s stock had a trading volume of 880,321 shares. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 29.42 and a beta of 1.02. Bruker Corporation has a 52-week low of $19.58 and a 52-week high of $28.35. The stock has a 50 day moving average price of $26.54 and a 200-day moving average price of $23.87.
Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.19 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.19. The business had revenue of $384.90 million for the quarter, compared to analyst estimates of $372.59 million. Bruker Corporation had a return on equity of 26.88% and a net margin of 9.35%. Bruker Corporation’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.21 EPS. Equities research analysts expect that Bruker Corporation will post $1.10 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 23rd. Shareholders of record on Monday, June 5th will be given a $0.04 dividend. The ex-dividend date of this dividend is Thursday, June 1st. This represents a $0.16 annualized dividend and a yield of 0.58%. Bruker Corporation’s payout ratio is 17.02%.
Institutional investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC increased its position in shares of Bruker Corporation by 131.2% in the first quarter. Piedmont Investment Advisors LLC now owns 36,420 shares of the medical research company’s stock valued at $850,000 after buying an additional 20,665 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in shares of Bruker Corporation by 0.7% in the first quarter. Public Employees Retirement System of Ohio now owns 48,267 shares of the medical research company’s stock valued at $1,126,000 after buying an additional 312 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Bruker Corporation by 2,261.9% in the first quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical research company’s stock valued at $26,890,000 after buying an additional 1,103,800 shares during the last quarter. Blue Sky Asset Management LLC acquired a new position in shares of Bruker Corporation during the first quarter valued at about $1,217,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Bruker Corporation during the first quarter valued at about $367,000. Hedge funds and other institutional investors own 67.52% of the company’s stock.
Several equities analysts have recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and set a $29.00 target price on shares of Bruker Corporation in a research note on Monday, May 15th. Deutsche Bank AG raised their price objective on Bruker Corporation from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Monday, May 15th. Cowen and Company raised their price objective on Bruker Corporation from $25.00 to $27.00 and gave the stock a “market perform” rating in a research note on Thursday, May 4th. Cleveland Research upgraded Bruker Corporation from a “neutral” rating to a “buy” rating in a research note on Thursday, April 27th. Finally, Janney Montgomery Scott cut Bruker Corporation from a “buy” rating to a “neutral” rating in a research note on Monday, March 27th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $25.00.
Bruker Corporation Company Profile
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Company’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST).
Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.